Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis

Rheumatology (Oxford). 2022 Feb 2;61(2):870-872. doi: 10.1093/rheumatology/keab776.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • COVID-19 / prevention & control
  • COVID-19 Vaccines / immunology*
  • Female
  • Giant Cell Arteritis / drug therapy*
  • Humans
  • Immunogenicity, Vaccine / immunology*
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Pandemics

Substances

  • COVID-19 Vaccines
  • Immunosuppressive Agents